Morningstar has issued a BUY recommendation on CRISPR Therapeutics AG (NASDAQ: CRSP), underscoring the stock’s significant undervaluation and robust long-term prospects, in its latest research repo
Motilal Oswal Securities has reiterated a BUY call on Lodha Developers, projecting a robust 36% upside with a revised target price of Rs 1,870 per share.